EE393 Assessing Cost-Effectiveness in Diabetes Management: A US Healthcare Payer’s Perspective on 15MG Tirzepatide Versus 1MG Semaglutide

Abstract

Authors

R Almasuood

Full Text Cite This Article
Back to Volume 27, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×